Overdue Novartis Adverse Event Report Submissions Cited In Warning Letter
Executive Summary
Novartis failed to make timely submissions of adverse event reports, FDA maintained in a Dec. 18 warning letter issued after an August inspection of Novartis' facility in Basel, Switzerland.